TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 28219442
Drug: Eplerenone 25
Normalized name: eplerenone 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Eplerenone 25 mg orally once daily for 24 months
Study: 22830537
Drug: Acid treatment
Normalized name: SALICYLIC ACID 20 mg in 1 mL TOPICAL GEL [Skin Laundry. Clean Slate Exfoliating 2 Salicylic Acid Treatment Gel Cleanser Cleanse Exfoliate]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acid treatment with methacrylate resin composite
Study: 23031319
Drug: Commercial attenuated
Normalized name: varicella, live attenuated
Approvals — FDA: no, EMA: no, PMDA: no
Description: Commercial attenuated vaccines
Study: 23031319
Drug: Experimental heterologous
Normalized name: Human heterologous liver cells
DrugBank: Heterologous human adult liver derived progenitor cells (DB17695)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Experimental heterologous (LV) inactivated vaccine
Study: 23031319
Drug: Commercial inactivated
Normalized name: diphtheria toxoid vaccine, inactivated / tetanus toxoid vaccine, inactivated Injection [Tdvax]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Commercial inactivated vaccine
Study: 23031319
Drug: Experimental homologous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Experimental homologous (08 V194) inactivated vaccine
Study: 23031319
Drug: Experimental heterologous
Normalized name: Human heterologous liver cells
DrugBank: Heterologous human adult liver derived progenitor cells (DB17695)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Experimental heterologous (07 V063 and LV) inactivated vaccines
Study: 23575220
Drug: Griseofulvin 25
Normalized name: griseofulvin 250 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Griseofulvin 25 mg/kg/day
Study: 23575220
Drug: Fluconazole 4
Normalized name: fluconazole 40 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluconazole 4 mg/kg/day
Study: 23575220
Drug: Fluconazole 6
Normalized name: Fluconazole
DrugBank: Fluconazole (DB00196)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Fluconazole 6 mg/kg/day
Study: 17584749
Drug: Cognitive-behavioural group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive-behavioural group treatment (CBT), n = 19
Study: 8606536
Drug: Extended-release felodipine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Extended-release felodipine (10 mg once daily)
Study: 8606536
Drug: Slow-release nifedipine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Slow-release nifedipine (20 mg twice daily)
Study: 361349
Drug: Glucamethacin (420
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glucamethacin (420 mg/day)
Study: 25079375
Drug: Topical application
Normalized name: Talc Topical application Powder
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical application of a mixture of two dimeticones of low viscosity (NYDA)
Study: 25079375
Drug: 0.05% solution
Normalized name: Equate Nasal Spray 0.05% Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.05% solution of KMnO4
Study: 18036292
Drug: Shenfu injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Shenfu injection (20 ml/L added to blood containing cardioplegic liquid)
Study: 6805791
Drug: No antibiotic
Approvals — FDA: no, EMA: no, PMDA: no
Description: No antibiotic prophylaxis
Study: 28835268
Drug: Preoperative antibiotic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Preoperative antibiotic prophylaxis (2000 mg of first-generation cephalosporin delivered intravenously)
Study: 24035939
Drug: Garlic tablets
DrugBank: Garlic (DB10532)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Garlic tablets at 600 mg
Study: 24035939
Drug: Garlic tablets
DrugBank: Garlic (DB10532)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Garlic tablets at 1200 mg
Study: 21242022
Drug: Pharmacological treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pharmacological treatment with exercise programme
Study: 12711266
Drug: Group cognitive
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group cognitive treatment for pathological gambling
Study: 16138577
Drug: Clinical treatment
Normalized name: DuoCare Clinical
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clinical treatment for patients with aberrant sperm nuclear proteins (n=30)
Study: 10077290
Drug: Manual-assisted cognitive-behaviour
Approvals — FDA: no, EMA: no, PMDA: no
Description: Manual-assisted cognitive-behaviour therapy (MACT)
Study: 6628517
Drug: Ketanserin 40
Normalized name: ketanserin 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketanserin 40 mg twice daily
Study: 3101865
Drug: Metoprolol 100
Normalized name: metoprolol 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metoprolol 100 mg twice daily
Study: 7032304
Drug: Gentamicin sulfate
Normalized name: Gentamicin Sulfate
DrugBank: Gentamicin (DB00798)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Gentamicin sulfate ophthalmic solution
Study: 27696593
Drug: Inappropriate shock
Normalized name: house dust allergenic extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inappropriate shock therapy
Study: 27696593
Drug: Appropriate shock
Normalized name: house dust allergenic extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Appropriate shock therapy
Study: 26072346
Drug: Patching (3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patching (3 hours daily for 5 months, followed by 1 month of no patching)
Study: 15281513
Drug: IV morphine
Approvals — FDA: no, EMA: no, PMDA: no
Description: IV morphine (0.125 mg/kg)
Study: 15281513
Drug: codeine (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: codeine (1 mg/kg)
Study: 15281513
Drug: tramadol (1.25
Approvals — FDA: no, EMA: no, PMDA: no
Description: tramadol (1.25 mg/kg)
Study: 15281513
Drug: placebo (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo (10 mL 0.9% w/v sodium chloride)
Study: 11199953
Drug: amisulpride 400
Normalized name: amisulpride 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: amisulpride 400 mg/day (N = 12)
Study: 11199953
Drug: olanzapine 20
Normalized name: olanzapine 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: olanzapine 20 mg/day (N = 13)
Study: 11199953
Drug: sertindole 12
Normalized name: sertindole 12 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: sertindole 12 mg/day (N = 13)
Study: 11199953
Drug: clozapine 100
Normalized name: clozapine 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: clozapine 100 mg/day (N = 13)
Study: 9449585
Drug: Betanecholchloride (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Betanecholchloride (50 mg three times a day from the 3rd postoperative day)
Study: 9449585
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (received betanecholchloride only if residual urine persisted above 50 ml after the 10th postoperative day)
Study: 31201809
Drug: Uterosacral ligament
Normalized name: human ligament preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Uterosacral ligament suspension
Study: 26715658
Drug: Outside brachial
Normalized name: Brachiara mutica pollen
DrugBank: Urochloa mutica pollen (DB10716)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Outside brachial plexus sheath injection
Study: 26420240
Drug: Conventional physical
Normalized name: hypochlorite
DrugBank: Hypochlorite (DB11123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional physical therapy with low-level laser therapy (protocol B)
Study: 26420240
Drug: Conventional physical
Normalized name: hypochlorite
DrugBank: Hypochlorite (DB11123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional physical therapy (protocol A)
Study: 23103498
Drug: BQ-123 (endothelin
Approvals — FDA: no, EMA: no, PMDA: no
Description: BQ-123 (endothelin type A receptor antagonist)
Study: 21968662
Drug: Tazarotene gel
Normalized name: Tazarotene
DrugBank: Tazarotene (DB00799)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tazarotene gel (0.1%) pretreatment for one week before ALA PDT
Study: 21968662
Drug: Tazarotene gel
Normalized name: Tazarotene
DrugBank: Tazarotene (DB00799)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tazarotene gel (0.1%) pretreatment
Study: 10916529
Drug: Inhaled beclomethasone,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled beclomethasone, mean daily dose of 2861 micrograms/day, decreasing during treatment.
Study: 9423108
Drug: Propofol (2.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propofol (2.5 mg/kg)
Study: 9725754
Drug: Lorazepam 0.026
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lorazepam 0.026 mg/kg
Study: 9725754
Drug: Lorazepam 0.038
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lorazepam 0.038 mg/kg
Study: 29752604
Drug: 4 mg
Normalized name: lutein 4 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 mg dexamethasone submucosally
Study: 27430336
Drug: Weekly care
Approvals — FDA: no, EMA: no, PMDA: no
Description: Weekly care management phone calls (CMPCs)
Study: 22561875
Drug: Rasagiline 2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rasagiline 2 mg/d
Study: 24919813
Drug: Rasagiline 1
Normalized name: rasagiline 1 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rasagiline 1 mg/d
Study: 8688340
Drug: Continuous tamoxifen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous tamoxifen therapy beyond 5 years
Study: 7740638
Drug: Stroke unit
Approvals — FDA: no, EMA: no, PMDA: no
Description: Stroke unit treatment
Study: 1505614
Drug: Indomethacin 25
Normalized name: indomethacin 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Indomethacin 25 mg tid for 6 days (young subjects)
Study: 1427426
Drug: Conventional chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional chemotherapy (hydroxyurea)
Study: 22289904
Drug: Dexamethasone (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexamethasone (1 mg/kg body weight) 4 hours before cardiopulmonary bypass
Study: 15929755
Drug: Non-eradication group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-eradication group (no treatment for H. pylori)
Study: 12628815
Drug: Single dose
Normalized name: Citrucel Single Dose Packets (Orange)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single dose (3.3 microg) of TBE vaccine
Study: 10656156
Drug: Group treatment
Normalized name: Allergenic Extracts Intradermal Kit [9 SO. GRASS GROUP TREATMENT SET]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group treatment based on psychosomatic and physio-therapeutical principles, cognitive and operant behavioral therapy, 2.5 hours per week for 10 weeks.
Study: 25641731
Drug: Aspirin (600
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspirin (600 mg)
Study: 22481427
Drug: MF59-adjuvanted vaccine
Normalized name: respiratory syncytial virus pre-fusion F protein
Approvals — FDA: no, EMA: no, PMDA: no
Description: MF59-adjuvanted vaccine containing 3.75 μg A/H1N1 antigen
Study: 22481427
Drug: MF59-adjuvanted vaccine
Normalized name: respiratory syncytial virus pre-fusion F protein
Approvals — FDA: no, EMA: no, PMDA: no
Description: MF59-adjuvanted vaccine containing 7.5 μg A/H1N1 antigen
Study: 22481427
Drug: Nonadjuvanted vaccine
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nonadjuvanted vaccine containing 15 μg A/H1N1 antigen
Study: 17666715
Drug: Group A:
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group A: Infusion of 0.025 to 0.1 microg x kg(‐1) x min(‐1) with a PCA bolus of 0.25 microg x kg(‐1)
Study: 17666715
Drug: Group B:
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group B: Infusion of 0.025 microg x kg(‐1) x min(‐1) with a PCA bolus increased from 0.25 to 1 microg x kg(‐1)
Study: 15469647
Drug: Probiotic (6.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Probiotic (6.5 x 10(9) Lactobacillus casei Shirota cells twice daily)
Study: 15469647
Drug: Prebiotic (lactulose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prebiotic (lactulose 10 g twice daily)
Study: 8659199
Drug: Atenolol 50
Normalized name: atenolol 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atenolol 50 mg/day
Study: 12888781
Drug: Cyproheptadine (4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cyproheptadine (4 mg)
Study: 3511127
Drug: Cromolyn-like agent
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cromolyn-like agent administered via a Nebulizer Chronolog, used four times a day for 12 weeks
Study: 3511127
Drug: Cromolyn-like agent
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cromolyn-like agent
Study: 31310464
Drug: Intermittent hypothermic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intermittent hypothermic blood solution
Study: 24613817
Drug: Meeting treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Meeting treatment targets for HbA1c, cholesterol, and blood pressure
Study: 350506
Drug: Previous formulation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Previous formulation
Study: 30390639
Drug: Standard treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard treatment without music (Control)
Study: 22318191
Drug: 20-mg long-acting
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20-mg long-acting methylphenidate
Study: 20973316
Drug: Control (250
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (250 mL of water)
Study: 17722615
Drug: Solifenacin 10
Normalized name: solifenacin 10 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Solifenacin 10 mg/day
Study: 8859935
Drug: placebo p.o.
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo p.o. + perindopril at 0.167 mg i.v. (day 1) and perindopril 2 mg p.o. (day 2)
Study: 8859935
Drug: enalapril 2.5
Normalized name: enalapril 2.5 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: enalapril 2.5 mg p.o.
Study: 8859935
Drug: perindopril 2
Normalized name: perindopril 2 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: perindopril 2 mg p.o.
Study: 8859935
Drug: enalapril therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: enalapril therapy
Study: 26728982
Drug: High-dose Shaoyao
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose Shaoyao Shujin tablet
Study: 26728982
Drug: Low-dose Shaoyao
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose Shaoyao Shujin tablet
Study: 20929121
Drug: Kunning Oral
Normalized name: CAMPHOR (SYNTHETIC) 9 g in 100 mL / METHYL SALICYLATE 5 g in 100 mL / MENTHOL 39 g in 100 mL / TURPENTINE OIL 18 g in 100 mL TOPICAL OIL [Chan Yat Hing She Kun Wool Lok Medicated Oil]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Kunning Oral Liquid (Control)
Study: 9661555
Drug: Epidural ketamine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epidural ketamine 60 mg administered before induction of anesthesia (Group 1)
Study: 9661555
Drug: Epidural ketamine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epidural ketamine 60 mg administered after the parietal peritoneum was closed (Group 2)
Study: 2598905
Drug: 300 mg
Normalized name: rutin 300 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 300 mg caffeine ingested at 2315 h
Study: 1103897
Drug: i.v. and
Approvals — FDA: no, EMA: no, PMDA: no
Description: i.v. and oral application of AR-DF 26
Study: 31283892
Drug: Combination CPP-ACP-cranberry
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination CPP-ACP-cranberry dentifrice
Study: 25677596
Drug: Tenecteplase 0.1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tenecteplase 0.1 mg/kg
Study: 19384673
Drug: Solifenacin flexible
Approvals — FDA: no, EMA: no, PMDA: no
Description: Solifenacin flexible dosing (5-10 mg)
Study: 19384673
Drug: Tolterodine 4
Normalized name: tolterodine 4 mg oral capsule, extended release
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tolterodine 4 mg sustained release (SR)
Study: 19384673
Drug: Placebo (assumed
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (assumed to be comparable to no treatment)
Study: 11336584
Drug: Proton-pump inhibitor
Approvals — FDA: no, EMA: no, PMDA: no
Description: Proton-pump inhibitor (PPI)-based triple therapy for 1 week
Study: 11336584
Drug: Ranitidine bismuth
Normalized name: RANITIDINE BISMUTH CITRATE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ranitidine bismuth citrate (RBC)-based triple therapy (PPI or RBC plus any two of metronidazole, amoxycillin, and clarithromycin) for 1 week
Study: 11336584
Drug: RBC-triple therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: RBC-triple therapy for resistant strains
Study: 11336584
Drug: General treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: General treatment regimens
Study: 7819706
Drug: 50 mg
Normalized name: talc 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 mg daily injections of intramuscular progesterone from days 2 to 14 after TVA
Study: 2891940
Drug: Oral mexiletine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral mexiletine (10 mg/kg bodyweight daily)
Study: 31442495
Drug: 250-μg patch
Approvals — FDA: no, EMA: no, PMDA: no
Description: 250-μg patch (epicutaneous immunotherapy for peanut allergy)
Study: 23179351
Drug: 300 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 300 mg/kg nickel chloride
Study: 19637959
Drug: Routine replacement
Approvals — FDA: no, EMA: no, PMDA: no
Description: Routine replacement of peripheral intravenous catheters at 72-96 hours
Study: 15282457
Drug: Continuous infusion
Normalized name: insulin pump cartridge,continuous infusion,BT and controller SUBCUT EACH
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous infusion of protamine sulphate (25 mg/h for 6 hours)
Study: 10325668
Drug: Granisetron (GR)
Normalized name: Granisetron
DrugBank: Granisetron (DB00889)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Granisetron (GR) 1 mg
Study: 10325668
Drug: Prochlorperazine (PCh)
Normalized name: Prochlorperazine
DrugBank: Prochlorperazine (DB00433)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Prochlorperazine (PCh) 10 mg
Study: 1680533
Drug: Azelastine (8
Approvals — FDA: no, EMA: no, PMDA: no
Description: Azelastine (8 mg)
Study: 6412508
Drug: Penicillin-V, 55
Approvals — FDA: no, EMA: no, PMDA: no
Description: Penicillin-V, 55 mg/kg/day for two days
Study: 6412508
Drug: Penicillin-V, 55
Approvals — FDA: no, EMA: no, PMDA: no
Description: Penicillin-V, 55 mg/kg/day for seven days
Study: 25114127
Drug: KAE609 (Cipargamin)
Normalized name: Cipargamin
DrugBank: Cipargamin (DB12306)
Approvals — FDA: no, EMA: no, PMDA: no
Description: KAE609 (Cipargamin) 1 to 300 mg single dose
Study: 25114127
Drug: KAE609 (Cipargamin)
Normalized name: Cipargamin
DrugBank: Cipargamin (DB12306)
Approvals — FDA: no, EMA: no, PMDA: no
Description: KAE609 (Cipargamin) 10 to 150 mg once daily for 3 days
Study: 22212720
Drug: Timothy immunotherapy
Normalized name: Timothy
DrugBank: Phleum pratense top (DB14179)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Timothy immunotherapy
Study: 7697274
Drug: Mite immunotherapy
Normalized name: House dust mite immunotherapy extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mite immunotherapy
Study: 28714728
Drug: Cognitive-behavioral therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive-behavioral therapy (CBT) plus contingency management (CM)
Study: 9005798
Drug: Ofloxacin administered
Normalized name: Ofloxacin
DrugBank: Ofloxacin (DB01165)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ofloxacin administered intravenously in a dose of 200 mg twice a day followed by oral use in the form of tablets in a dose of 200 mg twice a day for 5 to 6 days.
Study: 9005798
Drug: Ofloxacin used
Normalized name: Ofloxacin
DrugBank: Ofloxacin (DB01165)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ofloxacin used orally in the form of tablets in a dose of 200 mg once a day in the morning for 5 to 7 days.
Study: 9005798
Drug: Ofloxacin used
Normalized name: Ofloxacin
DrugBank: Ofloxacin (DB01165)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ofloxacin used in the same dosage but in combination with some other antibiotics.
Study: 9005798
Drug: Antibiotics except
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antibiotics except for ofloxacin.
Study: 1752022
Drug: High tidal
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High tidal volume (HVT, 12.7 ml.kg‐1) ventilation
Study: 1752022
Drug: Conventional tidal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional tidal volume (CVT, 7.5 ml.kg‐1) ventilation
Study: 6753115
Drug: Pirenzepine (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pirenzepine (100 mg/day for six weeks)
Study: 26852726
Drug: Oral moxifloxacin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral moxifloxacin (400 mg on days 1-7)
Study: 26852726
Drug: Oral solithromycin
Normalized name: roxithromycin Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral solithromycin
Study: 17502431
Drug: Triazolam (0.25,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Triazolam (0.25, 0.5, and 0.75 mg)
Study: 10445371
Drug: Zaleplon (25,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zaleplon (25, 50, and 75 mg)
Study: 29746955
Drug: Micafungin 100
Normalized name: micafungin 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Micafungin 100 mg intravenously daily
Study: 29746955
Drug: Posaconazole suspension
Normalized name: Posaconazole
DrugBank: Posaconazole (DB01263)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Posaconazole suspension 400 mg orally twice daily
Study: 21518127
Drug: 20 IU
Normalized name: Calcium/Phosphorus/Vitamin D 105 MG-81 MG-120 IU Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 IU oxytocin dissolved in 30 mL saline (n=26)
Study: 21518127
Drug: Ergometrine 0.2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ergometrine 0.2 mg dissolved in 30 mL saline (n=27)
Study: 21518127
Drug: Misoprostol 800
Normalized name: Misoprostol
DrugBank: Misoprostol (DB00929)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Misoprostol 800 µg dissolved in 30 mL saline (n=25)
Study: 17086737
Drug: 0.5 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5 mg/kg of oral midazolam 20 minutes prior to dental treatment
Study: 3064641
Drug: Bedtime ethanol
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Bedtime ethanol (2 ml/kg of 100 proof vodka mixed in orange juice)
Study: 29761006
Drug: Intravenous sodium
Normalized name: immunoglobulins, intravenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous sodium valproate, 30 mg/kg as loading dose and then 4-8 mg/kg every 8 hr as maintenance regimen
Study: 29761006
Drug: Intravenous phenytoin
Normalized name: Phenytoin
DrugBank: Phenytoin (DB00252)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous phenytoin (IV PHT) 20 mg/kg as loading dose and then 1.5 mg/kg for 8 hr as maintenance therapy
Study: 22963271
Drug: Homeopathic combination
Normalized name: Urtica urens homeopathic preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Homeopathic combination remedy dysto-loges S
Study: 20636249
Drug: Brief individual
Normalized name: chloroxylenol
DrugBank: Chloroxylenol (DB11121)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Brief individual cognitive behavioral counseling comprising three weekly 1 hour sessions (n = 33)
Study: 15998903
Drug: Tamoxifen (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tamoxifen (20 mg daily)
Study: 17389658
Drug: Etanercept 50
Normalized name: etanercept 50 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Etanercept 50 mg once-weekly (QW)